Full index of posts »
Cytokinetics: New Collaboration With Astellas On CK-2127107 Greatly Improves Investment Outlook http://seekingalpha.com/p/24u9p Dec 24, 2014
Neuralstem: Some Encouraging, But Very Early, Information On Chinese Ischemic Stroke Trial Using NSI-566... http://seekingalpha.com/p/24hf7 Dec 18, 2014
Northwest Biotherapeutics: An Analysis Of What We Know About DCVax Direct $NWBO http://seekingalpha.com/a/1mb2j Dec 1, 2014
- ceristeare on Delay In Quick Shot Testosterone Clinical Program Is Not A Major Setback For The Stock (ATRS, Buy, $2.53) Agreed, looking to buy once the dust settles.
- ceristeare on Cytokinetics: New Collaboration With Astellas On CK-2127107 Greatly Improves Investment Outlook Happy Holidays to you Agent Smith. Thanks for t...
- Bio Bull on Neuralstem: Some Encouraging, But Very Early, Information On Chinese Ischemic Stroke Trial Using NSI-566 Stem Cells It's been tough digging anything up on the over...
- PICOLOMINI on Derma Sciences: Highlights Of The June 17th Analysts' Meeting Is there any conflict in expectations if and wh...
- BILLYJIMBOB1 on My Dialogue With Adam Feuerstein On Northwest Biotherapeutics Fighting seems appropriate if it is for good ca...
- Northwest Biotherapeutics' DC Vax Cancer Vaccine May Be A Game Changer In Cancer Therapy (11 Comments)
- If You're Going To San Francisco (10 Comments)
- My Dialogue With Adam Feuerstein On Northwest Biotherapeutics (7 Comments)
- Northwest Biotherapeutics (NWBO, $6.06, Buy): Comments On First Interim Look At DCVax-L Trial And Recent Weakness In The Stock (7 Comments)
- Neuralstem (CUR, Buy, $4.48) Publishing Of Phase 1 Results In Annals Of Neurology Causes Price Surge (4 Comments)